The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that
class action litigation has been brought on behalf of those who
purchased or otherwise acquired the securities of Sanofi (“Sanofi” or
the “Company”) (NYSE: SNY) between February 7, 2013 and December 3,
2014, inclusive (the “Class Period”).
If you purchased or otherwise acquired Sanofi securities during the
Class Period, you may move the Court for appointment as lead plaintiff
by no later than February 2, 2015.
Baxter International Inc. (NYSE:BAX) today announced that the company
has submitted a biologics license application (BLA) to the United States
(U.S.) Food and Drug Administration (FDA) for the approval of BAX111,
the first highly-purified recombinant von Willebrand Factor (rVWF) in
clinical development as a treatment for patients with von Willebrand
disease, the most common type of inherited bleeding disorder.
By Anora Mahmudova and Sara Sjolin, MarketWatch
AbbVie jumps on FDA's hepatitis C drug approval
NEW YORK (MarketWatch) -- U.S. stock futures were slightly higher on Monday amid some year-end deal making in a shortened Christmas week.
American Apparel Inc.'s stock (APP) rallied 7.5% in premarket trade Monday, after the apparel company said it has received an "indication of interest" to acquire the company for $1.30 to $1.40 a share.
By Ian Walker
LONDON--The U.K.'s Financial Reporting Council on Monday said it has launched an investigation into Tesco PLC's accounts for fiscal 2012, 2013 and 2014, following the recent accounting scandal at the supermarket chain.
Cerus Corporation (NASDAQ:CERS) announced today that its Phase 2
clinical trial of red blood cells treated with the INTERCEPT Blood
System met its primary endpoint, with preliminary analysis demonstrating
that greater than 75 percent of treated red blood cells continued to
circulate 24 hours following transfusion.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.